A detailed history of Cetera Investment Advisers transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 48,082 shares of RXRX stock, worth $274,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,082
Previous 51,189 6.07%
Holding current value
$274,067
Previous $383,000 17.49%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$5.92 - $8.6 $18,393 - $26,720
-3,107 Reduced 6.07%
48,082 $316,000
Q2 2024

Aug 22, 2024

BUY
$7.35 - $10.05 $35,985 - $49,204
4,896 Added 10.58%
51,189 $383,000
Q1 2024

May 24, 2024

BUY
$9.13 - $15.52 $422,655 - $718,467
46,293 New
46,293 $461,000
Q4 2023

Feb 13, 2024

BUY
$5.09 - $10.79 $65,009 - $137,809
12,772 New
12,772 $125,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.03B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.